tert-butyl 2-cyclohexyl-2-oxoethyl-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate | 1201187-50-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 2-cyclohexyl-2-oxoethyl-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate
• 英文别名: tert-butyl 2-cyclohexyl-2-oxoethyl(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate；tert-butyl N-(2-cyclohexyl-2-oxoethyl)-N-[5-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyrazin-2-yl]carbamate
• CAS: 1201187-50-9
• 化学式: C₂₆H₃₂N₄O₅S
• 分子量: 512.63
• InChiKey: SJBHHCSABIOHPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  120
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-cyclohexyl-2-oxoethyl-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate 在 五氟丙酸酐 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 4.0h， 生成 8-cyclohexyl-3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine
  参考文献：
  名称：

  Design and synthesis of tricyclic cores for kinase inhibition

  摘要：

  Interest in therapeutic kinase inhibitors continues to grow beyond success in oncology. To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores. We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine. Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.108
• 作为产物：
  描述：

  N-甲苯磺酰基-5-溴-4,7-二氮杂吲哚 在 palladium diacetate 、 sodium hydride 、 potassium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 2-甲基-2-丁醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 tert-butyl 2-cyclohexyl-2-oxoethyl-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate
  参考文献：
  名称：

  Design and synthesis of tricyclic cores for kinase inhibition

  摘要：

  Interest in therapeutic kinase inhibitors continues to grow beyond success in oncology. To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores. We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine. Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.108

文献信息

• Novel Tricyclic Compounds
  申请人：Wishart Neil

  公开号：US20090312338A1

  公开（公告）日：2009-12-17

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  这项发明提供了一个符合Formula (I)的化合物，其中包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤疾病有用。
• Tricyclic compounds
  申请人：Wishart Neil

  公开号：US08962629B2

  公开（公告）日：2015-02-24

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供一种公式（I）的化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和同分异构体，在此定义变量。本发明的化合物可用于治疗免疫和肿瘤疾病。
• NOVEL TRICYCLIC COMPOUNDS
  申请人：AbbVie Inc.

  公开号：US20150210708A1

  公开（公告）日：2015-07-30

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供了公式(I)的化合物，其包括药物可接受的盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此定义。本发明的化合物可用于治疗免疫和肿瘤疾病。
• TRICYCLIC KINASE INHIBITORS
  申请人：AbbVie Inc.

  公开号：EP3031324A2

  公开（公告）日：2016-06-15

  The invention provides a compound of Formula (Ie), pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供了式(Ie)化合物、药学上可接受的盐、原药、生物活性代谢物、立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学疾病。
• TRICYCLIC COMPOUNDS
  申请人：AbbVie Inc.

  公开号：EP2299821B1

  公开（公告）日：2015-11-04